AR050158A1 - Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion - Google Patents
Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicionInfo
- Publication number
- AR050158A1 AR050158A1 ARP050102327A ARP050102327A AR050158A1 AR 050158 A1 AR050158 A1 AR 050158A1 AR P050102327 A ARP050102327 A AR P050102327A AR P050102327 A ARP050102327 A AR P050102327A AR 050158 A1 AR050158 A1 AR 050158A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- hydrogen
- group
- unsubstituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- -1 pyrrolopyridine compound Chemical class 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 abstract 1
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de pirrolopiridina de formula (1), en donde: X1 es NR12 y X2 y X3 conjuntamente forman un grupo -CR13=CR11- o X3 es NR12 y X2 y X1 conjuntamente forman un grupo -CR13=CR11-; R1 se selecciona entre hidrogeno, alquilo C1-6, cicloalquilo C2-6 y alquilo C1-6 sustituido con halo; R2 es hidrogeno o (CH2)mR3 donde m es 0 o 1; o R1 y R2 junto con el átomo de N al que están unidos forman un anillo heterociclilo de 4 a 8 miembros no aromático opcionalmente sustituido; R3 es un grupo heterociclilo de 4 a 8 miembros no aromático, un grupo cicloalquilo C3-8, alquilo C1-0 lineal o ramificado, un alquenilo C2-10, un cicloalquenilo C3-8, un alquinilo C2-10, un cicloalquinilo C3-8 o un grupo fenilo, pudiendo estar cualquiera de ellos sin sustituir o sustituido, o R5; R4 se selecciona entre hidrogeno, alquilo C1-6, cicloalquilo C3-6, alquilo C1-6 sustituido con halo, COCH3, y SO2Me; R5 es una formula (2), en donde: p es 0, 1 o 2, y X es CH2, O, S, o SO2; R6 es fenilo sin sustituir o sustituido, cicloalquilo C3-6 sin sustituir o sustituido o un anillo heterociclilo de 4 a 8 miembros no aromático sustituido; o R4 y R6 junto con el átomo de N al que están unidos forman un anillo heterociclo de 4 a 8 miembros no aromático opcionalmente sustituido; R7 es OH, alcoxi C1-6, NR8aR8b, NHCOR9, NHSO2R9 o SOqR9; R8a es H o alquilo C1-6; R8b es H o alquilo C1-6; R9 es alquilo C1-6; R10 es hidrogeno, alquilo C1-6 sustituido o sin sustituir o cloro; R11 es hidrogeno o alquilo C1-6; R12 es hidrogeno o alquilo C1-6; R13 es hidrogeno o alquilo C1-6; q es 0, 1 o 2; o un derivado farmacéuticamente aceptable del mismo, donde el compuesto no es (tetrahidro-piran-4-il)-amida del ácido 3-metil-7-morfolin-4-il-1H- pirrolo[2,3-c]piridina-4-carboxílico o (tetrahidro-piran-4-ilmetil)-amida del ácido 3-metil-7-morfolin-4-il-1H-pirrolo[2,3-c]piridina-4-carboxílico. Composicion farmacéutica que lo comprende y uso del compuesto para prepararla. Este compuesto se aplica en el tratamiento de afecciones mediadas por la actividad del receptor de cannabinoides 2, como ser trastorno inmune o inflamatorio, dolor inflamatorio, visceral, de cáncer, neuropático, lumbar, musculoesquelético, postoperatorio, agudo y migrana, artritis reumatoide, esclerosis multiple, osteoartritis u osteoporosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0412908A GB0412908D0 (en) | 2004-06-09 | 2004-06-09 | Compounds |
| GB0424950A GB0424950D0 (en) | 2004-11-11 | 2004-11-11 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050158A1 true AR050158A1 (es) | 2006-10-04 |
Family
ID=34969264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102327A AR050158A1 (es) | 2004-06-09 | 2005-06-07 | Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7589206B2 (es) |
| EP (1) | EP1753764B1 (es) |
| JP (1) | JP2008501758A (es) |
| KR (1) | KR20070034049A (es) |
| AR (1) | AR050158A1 (es) |
| AT (1) | ATE412651T1 (es) |
| AU (1) | AU2005251913A1 (es) |
| BR (1) | BRPI0511874A (es) |
| CA (1) | CA2569887A1 (es) |
| DE (1) | DE602005010698D1 (es) |
| DK (1) | DK1753764T3 (es) |
| ES (1) | ES2317244T3 (es) |
| HK (1) | HK1104175A1 (es) |
| HR (1) | HRP20090034T3 (es) |
| IL (1) | IL179603A0 (es) |
| MA (1) | MA28686B1 (es) |
| MX (1) | MXPA06014471A (es) |
| NO (1) | NO20070067L (es) |
| PE (1) | PE20060430A1 (es) |
| PL (1) | PL1753764T3 (es) |
| PT (1) | PT1753764E (es) |
| RU (1) | RU2006147278A (es) |
| SI (1) | SI1753764T1 (es) |
| TW (1) | TW200611695A (es) |
| UY (1) | UY28945A1 (es) |
| WO (1) | WO2005121140A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ544331A (en) | 2003-07-22 | 2010-03-26 | Arena Pharm Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| CA2569887A1 (en) | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| KR20070053231A (ko) * | 2004-07-28 | 2007-05-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 피롤로[2,3-ｃ]피리딘 화합물, 그 제조 방법 및 용도 |
| AU2005280740B2 (en) * | 2004-09-03 | 2011-04-28 | Yuhan Corporation | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof |
| PE20070239A1 (es) * | 2005-08-09 | 2007-04-01 | Glaxo Group Ltd | Derivados de imidazopiridina con actividad sobre los receptores cannabinoides |
| GB0516379D0 (en) * | 2005-08-09 | 2005-09-14 | Glaxo Group Ltd | Compounds |
| WO2007118041A1 (en) * | 2006-04-07 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| JP2010521516A (ja) * | 2007-03-21 | 2010-06-24 | グラクソ グループ リミテッド | 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用 |
| GB0705803D0 (en) * | 2007-03-28 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| US8524727B2 (en) | 2009-03-30 | 2013-09-03 | Astellas Pharma Inc. | Pyrimidine compound |
| TW201200518A (en) * | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| PT2599774T (pt) * | 2010-07-29 | 2016-09-23 | Astellas Pharma Inc | Compostos de piridina condensados como ligandos do recetor canabinoide cb2 |
| EP2827846B1 (en) * | 2012-03-19 | 2020-08-12 | Sharon Anavi-Goffer | Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists |
| RU2708395C2 (ru) | 2013-06-26 | 2019-12-06 | Эббви Инк. | Первичные карбоксамиды в качестве ингибиторов bтk |
| EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
| RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
| US11053241B2 (en) * | 2018-11-30 | 2021-07-06 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| US11891394B1 (en) | 2023-09-06 | 2024-02-06 | King Faisal University | Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors |
| US11858935B1 (en) | 2023-09-06 | 2024-01-02 | King Faisal University | Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3379404D1 (en) * | 1982-12-29 | 1989-04-20 | Kureha Chemical Ind Co Ltd | Cephalosporin derivatives |
| CA2031927A1 (en) | 1989-12-27 | 1991-06-28 | Imperial Oil Limited | Method for improving the activity maintenance of a plasma initiator |
| WO1991009598A1 (en) | 1990-01-05 | 1991-07-11 | Pfizer Inc. | Azaoxindole derivatives |
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| GB9109246D0 (en) | 1991-04-30 | 1991-06-19 | Ici Plc | Nitrogen derivatives |
| DE4129603A1 (de) | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| TW263504B (es) | 1991-10-03 | 1995-11-21 | Pfizer | |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5468757A (en) | 1994-01-31 | 1995-11-21 | Eli Lilly And Company | 6-azaindole thromboxane synthase inhibitors |
| DE69502587T2 (de) | 1994-02-18 | 1998-11-26 | Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn. | 2-heteroaryl-5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e] [1,4]diazepine und ihre verwendung zur vorbeugung und behandlung von hiv-infektion |
| GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
| US5589482A (en) | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
| JPH0920779A (ja) | 1995-05-01 | 1997-01-21 | Japan Tobacco Inc | 縮合ヘテロ５員環アゼピン化合物類及びその医薬用途 |
| GB9610811D0 (en) | 1996-05-23 | 1996-07-31 | Pharmacia Spa | Combinatorial solid phase synthesis of a library of indole derivatives |
| US6696448B2 (en) | 1996-06-05 | 2004-02-24 | Sugen, Inc. | 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors |
| EP0927167A1 (en) | 1996-08-14 | 1999-07-07 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| EP0984930B1 (en) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| EP0931872B1 (de) | 1998-01-23 | 2003-04-09 | Voith Paper Patent GmbH | Verfahren zur Entfernung von feinen Verunreinigungen aus einer Faserstoffsuspension |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CA2342222A1 (en) | 1998-08-31 | 2000-03-09 | Sugen, Inc. | Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity |
| GB9904995D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Substituted aza-oxindole derivatives |
| CA2367113A1 (en) | 1999-03-10 | 2000-09-14 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| JP2002538205A (ja) | 1999-03-10 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物 |
| CA2367130A1 (en) | 1999-03-10 | 2000-09-14 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| EP1165076A4 (en) | 1999-03-10 | 2002-05-15 | Merck & Co Inc | 6-AZAINDOL COMPOUNDS AS GONADOLIBERINE'S ANTAGONISTS |
| AU3868900A (en) | 1999-03-10 | 2000-09-28 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| JP2002539124A (ja) | 1999-03-10 | 2002-11-19 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物 |
| EP1181296A1 (en) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JP2004509059A (ja) | 1999-06-03 | 2004-03-25 | アボット・ラボラトリーズ | 細胞接着抑制性抗炎症化合物 |
| EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US20020061892A1 (en) | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
| EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| SK15432002A3 (sk) | 2000-04-28 | 2004-01-08 | Baxter Healthcare Sa | 2-acylindolové deriváty a ich použitie ako protinádorového prípravku |
| RU2269523C2 (ru) | 2000-04-28 | 2006-02-10 | Акадиа Фармасьютикалз, Инк. | Мускариновые агонисты |
| JP4911864B2 (ja) | 2000-08-14 | 2012-04-04 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換ピラゾール |
| US7332494B2 (en) | 2000-08-14 | 2008-02-19 | Janssen Pharmaceutica, N.V. | Method for treating allergies using substituted pyrazoles |
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| RU2003106192A (ru) | 2000-09-06 | 2004-07-27 | Орто-Макнейл Фармасьютикал, Инк. (Us) | Способ лечения аллергий |
| EP1315492B1 (en) | 2000-09-06 | 2008-07-30 | Ortho-McNeil Pharmaceutical, Inc. | Use of substituted pyrazoles for the treatment of allergies |
| AU2002211828A1 (en) | 2000-10-02 | 2002-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP2004520365A (ja) | 2001-01-17 | 2004-07-08 | アミュラ テラピューティクス リミテッド | クルジパインおよび他のシステインプロテアーゼの阻害剤 |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| NZ527193A (en) | 2001-02-02 | 2004-05-28 | Bristol Myers Squibb Co | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US6951848B2 (en) | 2001-03-12 | 2005-10-04 | Millennium Pharmaceuticals, Inc., | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| ATE348097T1 (de) | 2001-04-09 | 2007-01-15 | Chiron Corp | Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten |
| CZ20033053A3 (en) | 2001-05-14 | 2004-05-12 | Bristol@Myersásquibbápharmaácompany | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| WO2003009852A1 (en) | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DE10143079A1 (de) | 2001-09-03 | 2003-05-15 | Zentaris Ag | Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel |
| AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| DE60216952T2 (de) | 2001-10-19 | 2007-07-05 | Transtech Pharma Inc. | Beta-carbolin-derivate als ptp-inhibitoren |
| DE10152306A1 (de) | 2001-10-26 | 2003-07-24 | Asta Medica Ag | 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften |
| TW200301251A (en) | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
| JP2005527542A (ja) | 2002-03-27 | 2005-09-15 | グラクソ グループ リミテッド | キノリンおよびアザインドール誘導体およびその５−ｈｔ６リガンドとしての使用 |
| AU2003224257A1 (en) | 2002-04-09 | 2003-10-27 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| US20040063744A1 (en) | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
| US6900206B2 (en) | 2002-06-20 | 2005-05-31 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives |
| TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| DE60304718T2 (de) | 2002-08-06 | 2007-04-26 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
| ES2273077T3 (es) | 2002-08-21 | 2007-05-01 | Glaxo Group Limited | Derivados de 2-fenilamino-4-trifluorometil-5 (bencil- o piridin-4-il-metil) carbamoilpirimidina como moduladores selectivos del receptor cannabinoide cb2. |
| GB0222493D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| AU2003279797B2 (en) | 2002-09-30 | 2009-10-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| FR2845388B1 (fr) | 2002-10-08 | 2004-11-12 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique |
| BRPI0407493A (pt) | 2003-02-14 | 2006-02-14 | Wyeth Corp | derivados heterociclil-3-sulfinilazaindol ou -azaindazol como ligantes de 5-hidroxitriptamina-6 |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| CA2569887A1 (en) | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
-
2005
- 2005-06-07 CA CA002569887A patent/CA2569887A1/en not_active Abandoned
- 2005-06-07 PL PL05747418T patent/PL1753764T3/pl unknown
- 2005-06-07 AR ARP050102327A patent/AR050158A1/es unknown
- 2005-06-07 WO PCT/EP2005/006182 patent/WO2005121140A1/en active Application Filing
- 2005-06-07 ES ES05747418T patent/ES2317244T3/es active Active
- 2005-06-07 PT PT05747418T patent/PT1753764E/pt unknown
- 2005-06-07 AT AT05747418T patent/ATE412651T1/de not_active IP Right Cessation
- 2005-06-07 BR BRPI0511874-3A patent/BRPI0511874A/pt not_active IP Right Cessation
- 2005-06-07 UY UY28945A patent/UY28945A1/es unknown
- 2005-06-07 PE PE2005000651A patent/PE20060430A1/es not_active Application Discontinuation
- 2005-06-07 DK DK05747418T patent/DK1753764T3/da active
- 2005-06-07 DE DE602005010698T patent/DE602005010698D1/de active Active
- 2005-06-07 EP EP05747418A patent/EP1753764B1/en active Active
- 2005-06-07 AU AU2005251913A patent/AU2005251913A1/en not_active Abandoned
- 2005-06-07 SI SI200530497T patent/SI1753764T1/sl unknown
- 2005-06-07 JP JP2007526300A patent/JP2008501758A/ja not_active Withdrawn
- 2005-06-07 US US11/570,099 patent/US7589206B2/en not_active Expired - Fee Related
- 2005-06-07 KR KR1020077000449A patent/KR20070034049A/ko not_active Application Discontinuation
- 2005-06-07 MX MXPA06014471A patent/MXPA06014471A/es unknown
- 2005-06-07 TW TW094118669A patent/TW200611695A/zh unknown
- 2005-06-07 RU RU2006147278/04A patent/RU2006147278A/ru not_active Application Discontinuation
-
2006
- 2006-11-27 IL IL179603A patent/IL179603A0/en unknown
- 2006-12-28 MA MA29569A patent/MA28686B1/fr unknown
-
2007
- 2007-01-04 NO NO20070067A patent/NO20070067L/no not_active Application Discontinuation
- 2007-08-16 HK HK07108940.7A patent/HK1104175A1/xx not_active IP Right Cessation
-
2009
- 2009-01-20 HR HR20090034T patent/HRP20090034T3/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005251913A1 (en) | 2005-12-22 |
| ATE412651T1 (de) | 2008-11-15 |
| IL179603A0 (en) | 2007-05-15 |
| PT1753764E (pt) | 2009-01-28 |
| BRPI0511874A (pt) | 2008-01-15 |
| UY28945A1 (es) | 2006-01-31 |
| MXPA06014471A (es) | 2007-03-21 |
| NO20070067L (no) | 2007-02-09 |
| WO2005121140A1 (en) | 2005-12-22 |
| TW200611695A (en) | 2006-04-16 |
| CA2569887A1 (en) | 2005-12-22 |
| US7589206B2 (en) | 2009-09-15 |
| EP1753764B1 (en) | 2008-10-29 |
| RU2006147278A (ru) | 2008-07-20 |
| ES2317244T3 (es) | 2009-04-16 |
| DE602005010698D1 (de) | 2008-12-11 |
| US20070219229A1 (en) | 2007-09-20 |
| HK1104175A1 (en) | 2008-01-04 |
| JP2008501758A (ja) | 2008-01-24 |
| SI1753764T1 (sl) | 2009-02-28 |
| DK1753764T3 (da) | 2009-02-16 |
| EP1753764A1 (en) | 2007-02-21 |
| KR20070034049A (ko) | 2007-03-27 |
| PL1753764T3 (pl) | 2009-04-30 |
| HRP20090034T3 (en) | 2009-03-31 |
| PE20060430A1 (es) | 2006-05-25 |
| MA28686B1 (fr) | 2007-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050158A1 (es) | Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion | |
| AR041016A1 (es) | Compuesto de pirimidina, composicion farmaceutica que lo comprende y uso del mismo para preparar dicha composicion | |
| AR065354A1 (es) | Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4. | |
| MXPA05010874A (es) | Compuestos n-heterociclicos condensados y su uso como antagonistas del receptor del factor liberador de corticotropina. | |
| DE602004021959D1 (de) | Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor | |
| MY145075A (en) | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists. | |
| AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
| TW200602338A (en) | Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions | |
| MX2008000115A (es) | Derivados de piperidina utiles como antagonistas de histamina h3. | |
| CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
| AR071285A1 (es) | Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos. | |
| HRP20070307T3 (en) | Derivatives of n-[ phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[ (azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | |
| NO20063468L (no) | Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister | |
| EA201070235A1 (ru) | Новые производные 6-триазолпиридинсульфанил-бензотиазола и -бензимидазола, способ их получения, применение их в качестве лекарственных средств, фармацевтические композиции и новое применение, а именно в качестве ингибиторов met | |
| PE20140146A1 (es) | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak | |
| WO2007017264A3 (en) | Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders | |
| RS54288B1 (en) | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | |
| BRPI0414592A (pt) | antagonistas de receptores de trombina | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| PE20080205A1 (es) | DERIVADOS DE PIRAZOLOPIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSIN QUINASA Tie2 | |
| SE0403171D0 (sv) | New compounds | |
| CY1108880T1 (el) | Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
| WO2008099072A3 (fr) | Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
| PE20200664A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| NO20060383L (no) | Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |